Please login to the form below

Not currently logged in
Email:
Password:

Hikma makes USD 163.6m cash offer for Arab Pharmaceutical

UK-based Hikma Pharmaceuticals has made a conditional offer to acquire Jordanian pharmaceutical company Arab Pharmaceutical Manufacturing (APM) for approximately USD 163.6m in cash.

UK-based Hikma Pharmaceuticals has made a conditional offer to acquire Jordanian pharmaceutical company Arab Pharmaceutical Manufacturing (APM) for approximately USD 163.6m in cash.

The generics company already has a significant presence in the Middle East and North Africa (MENA) region, the US and Europe.

The APM offer is conditional upon the successful completion of due diligence and the approval of APM shareholders.

Merrill Lynch International is acting as financial advisor to Hikma for the transaction.

Hikma is currently trading at GBP 445.20 on the LSE, up GBP 0.020 or 0.04 per cent.

For H1 FY07, Hikma racked up USD 224.9m in revenue, compared with USD 154.9m in H1 FY06, a rise of 45.2 per cent. Operating profit was 51.8m, compared with USD 42.2m. Diluted EPS was USD 20.2m, compared with USD 17.2m, an increase of 17.4 per cent.

In H1 FY07, Hikma began production at its new cephalosporin plant in Portugal for the MENA region and Europe. The company also entered the injectable oncology market through the acquisitions of Ribosepharm and Thymoorgan in Germany and acquired 10 new oncology products. The company also entered the Egyptian market when it signed an agreement to acquire Alkan Pharma in August 2007.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

The search for treatments for Parkinson’s disease
The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
Ditch the Label – it’s just me....
The impact of COVID-19 on clinical trials
As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...

Infographics